Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass compounding and deceptive marketing" of what it claimed were "illegitimate, knockoff versions" of its obesity therapy Wegovy (semaglutide).

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims’ compounding and deceptive marketing practices.